The IPKat has received and is pleased to host the following guest contribution by Kimberley Evans (Pearce IP) regarding a recent Australian decision concerning inter alia the honest concurrent use and own name defences under Australian trade mark law. Here’s what Kimberley writes:
Fanatics about trade mark infringement, cancellation and honest concurrent use in Australia
9 August 2024 | Sandoz Reports Q2/24 and Half Year Financial Results - 37% Biosimilar Growth On 9 August 2024, Sandoz announced its Q2 2024 sales and financial results for half...
2 August 2024 | AU | Novo Nordisk Launches Wegovy® (Semaglutide) in Australia On 2 August 2024, Australia’s Therapeutic Goods Administration announced that, according to Novo...
26 July 2024 | EU | New Indication Alert: EU Approves AbbVie’s Skyrizi® (Risankizumab) for UCOn 26 July 2024, AbbVie announced European Commission approval of Skyrizi®...
CQMS has successfully opposed ESCO Group’s (ESCO) patent application AU 2018201726 (‘726) on the grounds of lack of support and sufficiency. We previously reported on an opposition between the same parties for a related patent family member AU 2018201710 (‘710). As with that case, the Delegate in the present opposition exercised his authority under section 60(3) of the Patents Act 1990 and raised the additional opposition ground of inutility, which was not asserted by CQMS.
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that the European Medicines Agency (EMA) accepted its marketing...
How to Handle Roadblocks with an Australian Patent Examiner
Apple Inc. [2024] APO 25 (25 June 2024)
Amazentis SA [2024] APO 27 (28 June 2024)
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's Disease On 11 and 12 July 2024, respectively, Eisai and...
Elanco Australasia Pty Ltd v Abbey Laboratories Pty Ltd [2024] FCA 640
WIPR Leaders released its annual global guide to the world’s leading practitioners last week, and we are delighted to have 10 Pearce IP leaders across Australia and New Zealand...
7 July 2024 | IN | Approval Alert: Zydus Life Sciences’ Biosimilar Nivolumab Approved in IndiaOn 7 July 2024, Medical Dialogues reported that Zydus Life Sciences’ biosimilar...
We are thrilled to welcome Rosie Stramandinoli as Pearce IP’s Special Counsel, Patent & Trade Mark Attorney (AU, NZ). Rosie joins Pearce IP with more than 30 years’ experience at the highest levels of private practice at one of Australia’s leading IP firms and in-house. This, combined with her background in chemistry and business, makes Rosie a perfect fit for Pearce IP’s life sciences clients.
We are thrilled to announce that Pearce IP has been honoured as Australasian Lawyer’s 2024 The Best Boutique Intellectual Property Law Firms in Australia!
28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech has announced the completion of phase 1 clinical trials of...
We are thrilled to announce that Pearce IP has been honoured as Australasian Lawyer’s 2024 The Best Boutique Intellectual Property Law Firms in Australia!
How claim types and form will influence enforcement strategies
CQMS Triumphs in Patent Opposition Against ESCO Group
14 June 2024 | AU | Approval Alert: Bayer’s High Dose Eylea® (aflibercept) Approved in Australia On 14 June 2024, Australia’s Therapeutic Goods Administration (TGA) approved...
CQMS Triumphs in Patent Opposition Against ESCO Group
We are proud to announce that two of Pearce IP’s Leaders, Adele Chadwick and Chris Vindurampulle, have been honoured by WIPR Diversity Top 100 2024.
We are proud to announce that two of Pearce IP’s Leaders, Adele Chadwick and Chris Vindurampulle, have been honoured by WIPR Diversity Top 100 2024.
31 May 2024 | EU | US | Europe’s CHMP Recommends Dupixent® (Dupilumab) as COPD Add-On Treatment On 31 May 2024, Regeneron and Sanofi announced that the Committee for Medicinal...
SARB Management Group Pty Ltd trading as Database Consultants Australia v Vehicle Monitoring Systems Pty Limited (No 2) [2024] FCAFC 53
24 MAY 2024 | EU | Shanghai Henlius’ & Organon’s Biosimilar Denosumab Applications Validated by EMA On 24 May 2024, Shanghai Henlius and Organon announced that the European...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
